2,273,792 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Fmr LLC

Fmr LLC bought a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 2,273,792 shares of the company’s stock, valued at approximately $57,913,000. Fmr LLC owned about 4.39% of Bicara Therapeutics at the end of the most recent reporting period.

Separately, First Turn Management LLC acquired a new position in shares of Bicara Therapeutics in the 3rd quarter valued at about $14,324,000.

Bicara Therapeutics Stock Performance

Shares of Bicara Therapeutics stock opened at $21.10 on Friday. Bicara Therapeutics Inc. has a 1-year low of $17.41 and a 1-year high of $28.09. The firm’s fifty day simple moving average is $21.73.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, research analysts forecast that Bicara Therapeutics Inc. will post -2.89 EPS for the current fiscal year.

Insider Transactions at Bicara Therapeutics

In other news, Director Ra Capital Management, L.P. bought 1,833,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were purchased at an average cost of $18.00 per share, with a total value of $32,994,000.00. Following the completion of the acquisition, the director now directly owns 4,303,418 shares in the company, valued at approximately $77,461,524. The trade was a 74.20 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder James E. Flynn purchased 70,000 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the transaction, the insider now owns 897,587 shares of the company’s stock, valued at $16,156,566. This represents a 8.46 % increase in their position. The disclosure for this purchase can be found here.

Analyst Ratings Changes

A number of equities analysts have issued reports on BCAX shares. Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 target price on the stock. TD Cowen started coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating on the stock. HC Wainwright initiated coverage on Bicara Therapeutics in a research note on Friday. They set a “buy” rating and a $42.00 price objective for the company. Rodman & Renshaw began coverage on Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 target price on the stock. Finally, Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price target for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $43.00.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.